Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Adolescent

Riddler SA, Haubrich R, A DiRienzo G, et al. "Class-sparing regimens for initial treatment of HIV-1 infection." N. Engl. J. Med.. 2008;358(20):2095-106.
Mugavero MJ, May M, Ribaudo HJ, et al. "Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study." J. Acquir. Immune Defic. Syndr.. 2011;58(3):253-60.
Dooley KE, Savic RM, Park J-G, et al. "Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers." Antimicrob. Agents Chemother.. 2015;59(6):3399-405.
Kalayjian RC, Spritzler J, Matining RM, et al. "Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction." AIDS. 2013;27(10):1563-71.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Acosta EP, Kendall MA, Gerber JG, et al. "Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily." Antimicrob. Agents Chemother.. 2007;51(9):3104-10.
Graham CS, Wells A, Liu T, et al. "Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection." AIDS. 2006;20(3):345-51.
Svensson EM, Aweeka F, Park J-G, Marzan F, Dooley KE, Karlsson MO. "Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis." Antimicrob. Agents Chemother.. 2013;57(6):2780-7.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Vogler MA, Patterson K, Kamemoto L, et al. "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188." J. Acquir. Immune Defic. Syndr.. 2010;55(4):473-82.
Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Erlandson KMace, Kitch D, Tierney C, et al. "Impact of randomized antiretroviral therapy initiation on glucose metabolism." AIDS. 2014;28(10):1451-61.
Umeh OC, Currier JS, Park J-G, Cramer Y, Hermes AE, Fletcher CV. "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men." J Clin Pharmacol. 2011;51(12):1665-73.
Ferreira MAR, Mangino M, Brumme CJ, et al. "Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control." Am. J. Hum. Genet.. 2010;86(1):88-92.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Smith KY, Tierney C, Mollan K, et al. "Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine." Clin. Infect. Dis.. 2014;58(4):555-63.
Livingston EG, Cohn SE, Yang Y, et al. "Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy." Obstet Gynecol. 2007;110(2 Pt 1):391-7.
Court R, Gordon M, Cohen K, et al. "Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy." Int. J. Antimicrob. Agents. 2016;48(2):158-62.

Pages